Alasdair Russell

Alasdair is passionate about translating scientific discoveries into real-world outcomes. His interests centre on exploiting engineering principles in biology to drive societal change. Alasdair has over 25 years’ experience in the fields of cancer, DNA repair, adult stem cell biology and genome editing. He is widely published, an inaugural editor of the CRISPR Journal, and has secured many prestigious research grants. In 2015 he established Cancer Research UK’s first genome editing facility. In 2020 he founded Zygosity, a company that sits at the interface between CRISPR technologies and AI. Alasdair has successfully raised both venture-backed and academic funding, has led and managed high-functioning teams of 50+, has consulted globally across life science, translational research and genome engineering and has filed patents in these sectors. An experienced C-suite exec, Alasdair also holds positions on various regulatory and ethics committees and has produced insight for governmental bodies to aid in driving regulatory change.